Nitrome Biosciences is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is on Parkinson's disease, the company aims to expand its proprietary platform to include other disease indications. Nitrome has been widely recognized, and has won multiple awards including the prestigious Target Advancement grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). For more information, please visit our website at www.nitromebiosciences.com.
Total raised: $38M
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 21.04.2020 | Series A | $38M | - | finsmes.co... |
Mentions in press and media 8
| Date | Title | Description | Source |
| 02.11.2021 | Nitrome Biosciences Appoints Pierre Beaurang, Ph.D., as Chie... | SAN FRANCISCO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc. (formerly Nitrome Biosci... | globenewsw... |
| 02.11.2021 | Nitrome Biosciences Appoints Pierre Beaurang, Ph.D., as Chie... | --Founder Irene Griswold-Prenner, Ph.D., Focuses on Role as Chief Scientific Officer— San Francisco... | svhealthin... |
| 02.11.2021 | Nitrome Biosciences Appoints Pierre Beaurang, Ph.D., as Chie... | Founder Irene Griswold-Prenner, Ph.D., Focuses on Role as Chief Scientific Officer SAN FRANCISCO, N... | marketscre... |
| 20.05.2020 | Nitrome Biosciences Raises $38M Series A Financing | - | mbcbiolabs... |
| 24.04.2020 | Nitrome Biosciences Raises $38M Series A | SAN FRANCISCO, CA, Nitrome Biosciences has closed a Series A financing of $38 million co-led by So... | vcnewsdail... |
| 23.04.2020 | Nitrome Biosciences Raises $38M Series A Financing to Advanc... | Nitrome Biosciences Raises $38M Series A Financing to Advance Therapeutics Targeting a Novel Group... | svhealthin... |
| 22.04.2020 | Nitrome Biosciences Raises $38M in Series A Financing | Nitrome Biosciences, a San Francisco, CA-based biopharmaceutical company developing a platform aroun... | finsmes.co... |
| 21.04.2020 | Nitrome Biosciences Raises $38M Series A | SAN FRANCISCO--(BUSINESS WIRE)--Nitrome Biosciences (Nitrome), a privately-held biopharmaceutical co... | citybizlis... |